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Abstract
Evolution of Avian Influenza (AI) viruses – especially of the Highly Pathogenic Avian Influenza (HPAI) H5N1 subtype – is a
major issue for the poultry industry. HPAI H5N1 epidemics are associated with huge economic losses and are sometimes
connected to human morbidity and mortality. Vaccination (either as a preventive measure or as a means to control
outbreaks) is an approach that splits the scientific community, due to the risk of it being a potential driving force in HPAI
evolution through the selection of mutants able to escape vaccination-induced immunity. It is therefore essential to study
how mutations are selected due to immune pressure. To this effect, we performed an in vitro selection of mutants from
HPAI A/turkey/Turkey/1/05 (H5N1), using immune pressure from homologous polyclonal sera. After 42 rounds of selection,
we identified 5 amino acid substitutions in the Haemagglutinin (HA) protein, most of which were located in areas of
antigenic importance and suspected to be prone to selection pressure. We report that most of the mutations took place
early in the selection process. Finally, our antigenic cartography studies showed that the antigenic distance between the
selected isolates and their parent strain increased with passage number.
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Introduction
Influenza A viruses belong to the family of orthomyxoviridae.
They are negative single-stranded RNA viruses with a segmented
genome that comprises 8 genes. Of these, the immunologically
most-important are the Haemagglutinin (HA) and Neuraminidase
(NA) genes, which encode for the corresponding proteins. There
exist 16 different types of HA and 9 of NA, proteins, thus
theoretically giving rise to 144 combinations [1–3].
Influenza viruses are known to undergo a process called
antigenic drift, whereby they continuously change their antigenic
and genetic properties. The absence of proof-reading and post-
replicative repair mechanisms characteristic of the RNA polymer-
ase of these viruses is an important factor of antigenic drift [4,5].
The most important outcomes of antigenic drift may be an
increased ability of the virus to avoid natural or acquired host-
immunity, as well as a possibility of breaching host-range barriers
[6–8]. Both the HA and the NA proteins are involved in the
process of antigenic drift with the HA implicated much more,
since it is the main target of neutralising antibodies and is known
to accumulate many point mutations in its epitope or antibody-
binding regions [9–13].
As is the case with many RNA viruses, Avian Influenza (AI)
viruses consist of quasi-species. The mutations leading to the
antigenic drift discussed above also result in variation in the viruses
that occur together in one site of replication. In a quasi-species
these different virus genomes act together as one larger genome
[14–17]. The result is a virus pool that contains variable sequences
[4], some of which may in combination offer the virus a
competitive advantage by enabling it to adapt to a variety of
situations [8,18,19].
Highly Pathogenic Avian Influenza (HPAI) H5N1 virus has
spread globally and has become endemic in several parts of the
world, which is unique for a HPAI strain. Moreover, transmission
to humans occurs sporadically with most of the incidents involving
poultry workers and handlers and their immediate family
members [20–22]. Human cases remain sporadic due to the fact
that human-to-human transmission of H5N1 is at present
inefficient [8,23–25]. Nevertheless, H5N1 viruses are known to
continuously undergo antigenic drift as well as gene re-assortment
and as such they may become transmissible between humans [26].
For example, recent studies claim to demonstrate airborne
transmission of HPAI H5N1 with particular mutations in ferrets
[27–30].
In the case of humans, world-wide vaccination against seasonal
influenza is implemented. Constant screening for new variants
ensures that vaccine preparations are up-to-date with currently
circulating strains, thus making the vaccines as efficient as possible.
In poultry however, vaccination against avian influenza is not as
common. Avian influenza is a major problem in most parts of the
world, especially South-East Asia, where mainly strains of the
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H5N1 subtype are endemic. In order to control HPAI outbreaks
and thus prevent potential transmission to humans, culling of
infected animals as well as pre-emptive culling is the most common
method of choice. This has a devastating effect on the economy. A
number of countries (i.e. People’s Republic of China, Hong Kong
SAR, Vietnam, Indonesia, South Korea, Mexico Pakistan and
Egypt) are implementing nation-wide vaccination programmes in
their fight against avian influenza especially of the H5N1 subtype
due to its implications for humans. Nevertheless, none of these
countries continuously updates the vaccines used so as to match
currently circulating strains based on data from screening
programmes, as is the case with human vaccines. In addition,
other problems identified in countries where vaccination is used to
control infection and transmission of HPAI include – but are not
limited to – lack of screening for emerging variants, cutting vaccine
doses for economical reasons and inadequately-trained personnel
administering the vaccine [31–35].
Before vaccination can be used as a strategy against AI, the
mechanisms by which selection of escape mutants takes place, as
well as, the genetic and – most importantly – antigenic distance
necessary for mutants to avoid vaccination-induced immunity
must be understood. Although abundant research has been done
in escape mutant selection using monoclonal antibodies (MAbs)
directed against specific epitopes [36–42], research using poly-
clonal sera to select for escape mutants is very scarce. For example,
a study by Lambkin et al. [43] selected for escape mutants either by
using antisera from mice immunised with inactivated influenza
virus or by using a panel of 2–3 MAbs, but in those panels one
MAb was consistently present at much higher concentrations
compared to the rest. Another study by Archetti and Horsfall [44],
selected for antigenic variants of influenza A virus in ovo in the
presence of heterologous immune sera. While the study was ahead
of its time (1950), the technology of gene sequencing and the
technique of antigenic cartography were not in place to allow a
comprehensive genetic and antigenic characterisation of the
mutants selected. Trying to gain an insight in the selection of
mutants using MAbs does not fully address the complexity of the
issue. On the other hand, research on escape mutant selection in
vaccinated poultry is largely limited to field observations,
collections and characterisations of isolates originating from some
of the countries where a vaccination programme is in place.
Although substantial and valuable information has resulted from
such research leading to a better understanding of the field
situation and its impact in immune escape [45–47], such field
studies have too many variables, making pinpointing the causes of
possible directional selection very difficult.
Genetic characterisation of mutants by sequencing various parts
of the genome (with an emphasis on the HA gene) and by
identifying the positions and possible functions of various amino
acid mutations in the HA protein, is a valuable tool used to
elucidate the genetic evolution of a virus. Nevertheless, it does not
say much about potential changes in antigenicity of new strains
and whether the vaccine used against the original strain would be
less effective against these new mutant strains.
To measure possible changes in antigenicity, antibody binding
assays are used. The Haemagglutination Inhibition (HI) assay is
the golden standard used for decades by laboratories worldwide
for surveillance of influenza strains and the characterisation of
their antigenic properties [48,49]. Nevertheless, although the HI
assay is a valuable tool and easy to perform, it provides somewhat
crude data on the magnitude of the antibody (serum) response
against a viral strain but not on the focus and breadth of this
response. Furthermore, variations in protocols and origin of red
blood cells, coupled with the wide spacing of the dilutions used in
these assays, may make results from extensive HI databases on
strains that have been tested worldwide difficult to interpret. In
addition, the multitude of raw data generated by such HI
databases makes them very difficult to be visualised as a whole.
It is precisely for these reasons that a new computational technique
called antigenic cartography was developed and is now used
widely by the WHO [50–53]. Antigenic maps involve the
construction of distance matrices between viral isolates as
measured by the HI assay, and the plotting of these distances in
a way that is analogous to a geographical map. The further the
distance between two strains, the greater the antigenic differences
between them [52]. Antigenic cartography not only allows for the
simple and immediate visualisation of HI data, but also gives an
insight into virus evolutionary dynamics by allowing us to compare
genetic changes (as reflected by sequencing and construction of
phylogenetic trees) to phenotypic changes (as reflected by antigenic
distances) [12]. Furthermore, combining genetic and antigenic
characterisation can provide insights on which particular areas in
the HA protein are sensitive to directional selection, and which
mutations can alter the antigenicity of strains. Finally, by having a
picture of the antigenic evolution of a virus, antigenic cartography
can help us decide whether vaccine updating is necessary [50–53].
In this study, we aim to study the evolution of AI viruses by
repeated in vitro exposure to targeted pressure from polyclonal
immune sera directed against the HA of HPAI H5N1 A/turkey/
Turkey/1/2005. We characterised the resulting mutants by
identifying the nucleotide and amino acid substitutions in the
HA gene and protein respectively and by examining and
quantifying whether these substitutions resulted in genetic and
antigenic differences between the mutants and the parent strain.
Furthermore, we broadened our antigenic characterisation by
including escape mutants previously described [54] and by
comparing these mutants to our own.
Materials and Methods
Ethics Statement
All animal experiments complied fully with Dutch Law and
were reviewed by the Dierexperimenten Commissie (DEC)
Animal Sciences Group, Lelystad (animal experiments ethical
committee) prior to being carried out. The animal experiments
necessary to produce the antisera as described below, were
approved by the committee: permit numbers 2010123 and
2011086. Provisions were made in the protocols to ameliorate
animal suffering, such as regular monitoring of animal facilities,
healthcare of animals and termination of animals by means of
cervical dislocation at the end of the experiment (or during the
experiment if serious health problems were noticed).
All experiments described in this paper were performed within
the High Containment Unit, in Bio-Safety Level 3+ (BSL3+)
facilities at the Central Veterinary Institute of Wageningen UR.
Experiments regarding selection of mutants and genetic
characterisation refer to CVI mutants only. Both the CVI mutants
as described here and the FLI mutants described in Ho¨per, et al.,
[51] were used for antigenic characterisation experiments such as
the generation of sera, HI assays and the construction of the
antigenic maps.
Preparation of H5N1 virus stock
HPAI H5N1 influenza strain A/turkey/Turkey/1/2005 (Clade
2.2.1) was used as a parent strain (from now on abbreviated to
H5N1 t/T). A stock was made by passaging the virus once in
Specific Pathogen-Free (SPF) 9-day-old Embryonated Chicken
Eggs (ECEs) obtained from Charles River Avian Vaccine Services.
Influenza Mutant Selection with Polyclonal Sera
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Standard Haemagglutination Assays (HA) were performed on the
allantoic fluids of individual ECEs and the samples with the same
HA titres were pooled. Another HA assay was performed to
determine the HA titre of the pooled samples. The pooled stock
had a HA titre of 64 Haemagglutination Units (HAU) and a
Tissue Infectious Dose 50 (TCID50) of 10
8.3/mL. All TCID50
assays were performed according to standard protocols and using
Madin Darby Canine Kidney (MDCK) cells.
Origin of Sera for Selection Experiments
The sera used for our selection experiments were obtained from
SPF animals vaccinated against a genetically-modified (GM)
H5N7 strain, with the HA gene originating from A/turkey/
Turkey/1/2005, inserted into the backbone of the HPAI H7N7
Dutch outbreak virus A/chicken/Netherlands/6215857/2003
(Peeters et al., Unpublished Results). Briefly, animals were
vaccinated with 0.1% paraformaldehyde-inactivated GM H5N7
in the presence of Stimune adjuvant (Prionics) at a 4:5 (v/v)
inactivated virus to Stimune ratio. Vaccination volume and route
were 0.5 mL intra-muscularly (leg muscle) respectively. The HA
protein content of the vaccine was 0.6 mg/0.5 mL. Twenty-one
days post-vaccination, the animals were vaccinated for a second
time with the same vaccine dose. Sera were collected 11 days after
second vaccination took place. The HI titre of each serum was
determined and sera with HI titres 27.5–210.5 (181–1448 units)
were pooled. The HI titre of the pooled sera used in the series of
experiments described in this paper was 29.5 (i.e. 724 units).
Determination of optimum serum dilution for selection
of mutants
Dilutions of sera in Dulbecco’s Phosphate Buffered Saline
(DPBS) ranging from 1:100 to 1:1600 were made. Each serum
dilution was incubated for 2 h at 37 uC with an equal volume of 24
(16) HAU of the parent strain. After the incubation, TCID50
assays were performed on virus incubated with each dilution. An
optimum serum dilution for starting the selection experiments was
defined as the dilution that resulted in a 10006 titre decrease from
the original TCID50 titre. As such, it was found that a 4006serum
dilution should be used for selection of mutants.
Selection of Mutants
Selection of mutants took place in vitro. In detail, for each
subsequent round of selection, 16 HAU of virus from the
immediately previous selection round (starting with the parent
strain) were incubated with an equal volume of H5 homologous
sera (starting with a 4006dilution) for 2 h at 37uC. As a control,
16 HAU of virus isolates from the same selection round were
incubated with the same dilution of non-immune sera (i.e. sera
derived from SPF chicken) as the one used for the selection with
immune sera. After the incubation, the control isolates (i.e. virus
incubated with non-immune sera) were diluted 10006 in DPBS in
order to reduce the number of live virus particles, so as to resemble
the reduction that had taken place in the selection isolates.
Passages took place in three 9- to 11-day-old ECEs inoculated with
200 mL of the selection isolate and diluted control isolates. The
inoculated ECEs were incubated at 37uC, 5% CO2 and were
checked for embryo deaths regularly. Dead embryos were
removed from the incubator, time of death was recorded and
the allantoic fluid was harvested. HA assays were performed on
the allantoic fluid of each ECE and the ones with the same or
similar (within 1 log2 difference) HA titre were pooled, had their
HA titre re-checked and used for the next selection round. The
same procedure was followed for 20 passages. After passage 20,
serum pressure on the virus isolates was gradually increased by
decreasing the dilution of sera the virus isolates were incubated
with until the last passage (passage 42). Criteria for decreasing
serum dilutions were an increase in the HA titre of the virus
isolated from the allantoic fluid compared to the input titre (16
HAU) and an earlier time of death of the embryos. As a
consequence of the continuous decrease in serum dilutions, a 1:5
dilution was used in the last rounds of selection, marking a
difference of 806 compared to the 1:400 used in the first 20
selection rounds. For both the selection and control isolates the
same serum dilutions were used throughout.
RNA Isolation/DNA Amplification
Viral RNA was isolated from the allantoic fluid of every 5th
passage (both for the selection and control isolates), using the High
Pure Viral RNA Kit (Roche) according to the manufacturer’s
instructions. First strand cDNA synthesis (RT-PCR) was carried
out on the isolated RNA material, using SuperScriptH III, First-
Strand Synthesis SuperMix (Invitrogen) and Uni12, a universal
RT primer (primer sequence available upon request). Amplifica-
tion of the cDNA was done using the Expand High Fidelity PCR
System (dNTPack) from Roche and one pair of primers amplifying
the entire HA gene (primer sequences available upon request).
The amplified HA was checked in a 1% agarose gel and the
PCR product was purified using the High Pure PCR Product
Purification Kit (Roche) as per manufacturer’s instructions. The
DNA content of the purified PCR product was measured
spectrophotometrically (NanoDropTM 1000, Thermo Scientific
Inc.).
Sequencing of the HA of mutants
Sequencing PCR on the purified PCR product took place using
4 pairs of forward and reverse primers spanning the entire length
of the gene with overlapping regions (primer sequences available
upon request).
DNA from sequencing PCR was precipitated and samples were
prepared for sequencing analysis, using the 3130 Genetic Analyser
(Hitachi/Applied Biosystems).
The SeqManTM software from DNASTAR LasergeneH 10
Core Suite was used to align, edit and compare the nucleotide
sequences of the passage isolates to the sequence of the parent
strain. Nucleotide sequences were translated into amino acid
sequences and aligned using the MegAlignTM software of the same
suite, and the positions of the mutations were noted.
Erythrocyte Binding Assays
Erythrocyte binding assays were performed to evaluate whether
there exists a difference between the H5N1 t/T parent strain and
the latest mutant, CVI Passage 42 (from now on abbreviated to
CVI P42) in their ability to bind to chicken erythrocytes. The
assays were performed in triplicate. To avoid any NA activity from
taking place, which would result in release of virus from the
erythrocytes, the assay was performed on ice for the entire
duration. Time points (0, 5, 10, 20, 30 and 40 minutes) were
introduced in order to evaluate the kinetics of virus binding to
erythrocytes. Finally, a ratio of 1000:1 erythrocytes:virus particles
was used. Both strains were diluted to 1.756104 virus particles/
200 mL and incubated on ice with an equal volume of 1%
erythrocytes (1.756107) from SPF chicken at the indicated time
points. As a control, the same amount and volume of viruses were
added to 200 mL of DPBS at time point 0 minutes. Immediately
after the incubation, the samples were centrifuged gently at
1500 rpm in a pre-cooled centrifuge to precipitate the erythro-
cytes, 200 mL of supernatant were removed from each time point
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and viral RNA was isolated with the MagNA Pure 96 system
(Roche Applied Sciences), using the MagNA Pure DNA and Viral
RNA Small Volume kit (Roche Applied Sciences) as per
manufacturer’s instructions. Quantitative R-RT-PCR (qPCR)
using the Mx-3005P (Stratagene) was used to quantify viral copies
after 45 cycles of amplification. The qPCR protocol and the AI
probe used were optimised to be specific to the highly conserved
gene encoding for the M protein of influenza A viruses. A standard
curve comprising of the H5N1 t/T strain was prepared and used
to analyse the data. The results from the qPCR were analysed
using the MxPro software (Stratagene). Since the results from the
triplicate measurements were highly reproducible (data not
shown), the mean of the three measurements for each time point
was used.
Inactivation of Viruses
All strains were inactivated by incubating virus stocks with
0.02% paraformaldehyde (Merck) for 16 h at 37uC. HA assays
were performed on the inactivated viruses before and after
inactivation to note HA titres. Complete inactivation was verified
by two passages in ECEs lasting 7 days each, followed by HA
assays at the end of each passage to check for the presence of live
virus. The inactivation was considered successful when the HA
assays at the end of each passage were negative for each strain.
The inactivated strains had their HA titres standardised to
26 (64) HAU by diluting them with negative allantoic fluid (i.e.
allantoic fluid originating from SPF ECEs).
Generation of Hyper-Immune Sera for Antigenic
Characterisation
In order to examine the antigenic differences between passage
isolates and their respective parent strains by means of construct-
ing antigenic maps, we generated sera in chickens, against a
number of selected strains.
In detail, we have raised sera against the parent strain
(H5N1 t/T) and the CVI P20 and CVI P42 isolates. In addition
to our isolates, sera were also raised against the FLI parent strain
(HPAI H5N1 A/Cygnus cygnus/Germany/R65/2006, from now
on abbreviated to H5N1 R65) and selected mutants (FLI P18esc
and FLI P30esc). These mutants are described in detail in Ho¨per
et al. [51].
For reasons of comparison and in addition to the parent strains
and mutants of both groups, sera were also raised against two
other HPAI H5 strains which are known to be antigenically
different from the parent strains used by both CVI and FLI. These
were A/chicken/Pennsylvania/1370/1983 (H5N2) and A/tern/
South Africa/1961 (H5N3).
A complete list of the strains used to produce sera in chickens, is
shown in Table 1.
All SPF animals used in our experiments originated from SPF
ECEs that were hatched in our HCU facilities. Two 6-week-old
SPF chickens per strain were each vaccinated intra-muscularly
with 0.5 mL of 64 HAU inactivated virus in the presence of
adjuvant (Stimune, Prionics) at a 4:5 (v/v) inactivated virus to
Stimune ratio. The animals were housed together and were
inspected twice a day. Three weeks post-vaccination, the animals
were bled, sera were collected and inactivated at 56uC for 50
minutes. The inactivated sera were stored at 220uC.
HI Assays
The titres of the inactivated sera were determined in HI assays
[48,49], in which 8 HAU of each strain were used as an antigen
for each one of the sera that were collected during the animal
experiments (i.e. homologous and heterologous sera). The assays
took place in duplicate. All 8 strains used for the generation of
hyper-immune sera were used in the HI assays. In addition, the
intermediate CVI passage isolates (CVI P5, P10, P15, P25, P30,
P35 and P40) were also used, in order to evaluate which isolates
are more suitable for use in antigenic cartography studies.
Construction of Virus Antigenic Map
Our HI dataset consisted of 16 sera that were raised against 8
strains (2 animals/strain). In addition, each serum measurement
was performed in duplicate.
To construct the virus antigenic map, we first averaged the
duplicate HI titres for each serum and converted the values into
log2 values. The result was a 1668 matrix.
We then calculated the difference in log2 titres between the
homologous (i.e. sera raised against the same strain) and
heterologous (i.e. sera raised against the remaining 7 strains)
scenarios. We standardised the differences to be $0, thus any
negative values were treated as 0. The result was a 1668 matrix
which depicts in each row the differences in HI titres between each
one of our 8 strains against each of the 16 sera.
The matrix was standardised so that the average of each virus
against each of the 16 sera would be 0 and the SD would be 1.
From this 8616 matrix (M) with the standardised differences,
the distances between strains were calculated in MathematicaH
(Version 8, Wolfram Research, Inc.) by applying the following
formula,
disti,j~
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃP16
k~1
mi,k{mj,k
 2s
where m is a matrix element of matrix M.
From the resulting symmetrical 868 distance matrix, we are
able to compare the distances between any set of three strains by
extracting the 363 distance sub-matrices of these strains and
solving the distance equations to obtain x, y coordinates for each
strain. As a result, this distance matrix can be presented on a
2-dimensional plane by plotting triangles that share one edge and
thus conserve the real distances between the viruses. Hence, in
such a plot distances between all viruses connected by a triangle
Table 1. List of strains used for antigenic cartography studies.
Strain Name
Accession
Number Origin
HPAI H5N1 A/turkey/Turkey/1/2005 EF619980 CVI
CVI P20 KF042152 CVI
CVI P42 KF042153 CVI
HPAI H5N2 A/chicken/Pennsylvania/
1370/1983
GU052771 CVI
HPAI H5N3 A/tern/South Africa/1961 GU052822 CVI
HPAI H5N1 A/cygnus cygnus/
Germany/R65/2006
EPI309750 FLI
FLI P18esc EPI287212 FLI
FLI P30esc EPI287220 FLI
Strains against which sera were raised for purposes of antigenic cartography. P
stands for Passage. In the interests of continuity, the same naming for the FLI
strains mentioned in [54] was kept.
doi:10.1371/journal.pone.0084628.t001
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represent the exact distance as found in the distance matrix but
this is not true for the viruses that do not share a triangle.
Construction of Sera Antigenic Map
To construct an antigenic map of the sera, the same procedure
was followed, but applying modifications to show the position of
each serum from each strain, relative to the sera of the other
strains. Our starting point was thus an 8616 matrix. By
constructing such a map, we also obtain information on the
differences in the immune responses of individual chicken.
Thus, the distance formula is modified as follows:
disti,j~
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃP8
k~1
mi,k{mj,k
 2s
Results
Genetic Characterisation of Passage Isolates by HA
Sequencing
Mutants were selected in the presence of homologous immune
sera. Serum dilutions were gradually lowered after passage 20 in
order to increase selection pressure. An overview of the serum
dilutions used for each passage appears in Table S1 in File S1.
Isolates from every 5th passage (both from the selection and
control lines) were selected for sequencing of the HA gene.
Nucleotide and amino acid substitutions were noted. The amino
acid numbering reported here refers to the reference H5N1 strain
A/goose/Guangdong/1/1996.
By the end of the selection (CVI P42), 5 amino acid mutations
were identified. Crucially, no amino acid substitutions were found
in the HA of the control passages. An overview of the amino acid
mutations found in the HA protein of our passage isolates as well
as the points in the selection process where these mutations were
identified are shown in Figure 1. CVI P20 and CVI P42 HA
nucleotide sequences were submitted to GenBank (Accession Nos:
KF042152 and KF042153 respectively).
Table 2 provides an overview of the HA mutations found in
CVI P42 and the antigenic sites (where identified) they fall into.
Interestingly, most of the mutations are located in previously-
identified Antigenic Sites (AS), and the Receptor Binding Site
(RBS). The exception is A254T, which falls in a region not
previously connected with antigenicity. In Table 2 a comparison of
the A/goose/Guangdong/1/1996 numbering with the numbering
of the two parent strains used by CVI and FLI (H5N1 t/T and
H5N1 R65 respectively) is also shown.
Antigenic Characterisation of Strains and Sera
In order to examine the antigenic differences between each
strain (i.e. parent strains and CVI and FLI variant strains), a series
of HI assays were performed, in which all sera obtained from
animals vaccinated against each strain were cross-checked against
each one of the strains. In addition, the intermediate CVI passage
isolates were also used in the assays. Regarding the CVI isolates,
based on the HI data and the construction of antigenic distance
matrices (Tables S4 and S5 respectively in File S1), it was decided
to show the CVI P20 and CVI P42 isolates in the antigenic maps
of strains and sera. This was because CVI P42 was found to be the
most distant isolate compared not only to the H5N1 t/T but also
the rest of the CVI isolates. In other words, to fully evaluate the
magnitude of the distance of any strain, its distances to all other
Figure 1. Amino acid mutations found in the HA of CVI passage isolates. Schematic representation of the mutations found in CVI passage
isolates. The number of amino acid mutations increases with passage number and serum pressure. First mutations are found as early as Passage 5
and are carried over to later passages. Only two additional mutations were found between Passage 20 and Passage 42, indicating that most of the
selection takes place in early passages. Black horizontal bar represents the progress of the passages. Blue vertical bars represent the time points
where HA sequencing took place and their height represents the number of amino acid mutations found at each time point.
doi:10.1371/journal.pone.0084628.g001
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strains have to be taken into consideration. For example, although
the distance between H5N1 t/T and CVI P40 appears to be
slightly larger than the distance between H5N1 t/T and CVI P42
(log22.61 and log22.17 respectively), the distance between CVI P40
and CVI P42 is also large (log21.38). This holds true for any strain
compared to CVI P42. Figure S1 in File S1 shows the distances of
all strains compared to H5N1 t/T and CVI P42. Figure S1 in File
S1 provides a map with coordinates (similar to latitude and
longitude in a geographical map) where each CVI strain is
positioned according to its distance from these two strains. From
Figure S1 in File S1 it becomes clear that the antigenic distance
between CVI P42 and – say – the cluster of CVI P5, P10 and P15
is larger than the distance of CVI P40 to the same cluster of
isolates, thus indicating the greater antigenic distance of CVI P42
across the whole spectrum of CVI strains. CVI P20 was chosen not
only because of its antigenic distance to other strains but also
because it represented a turning point in our selection process
(from a steady immune pressure up to CVI P20 to a progressively
increased pressure from there on). Due to these results, the 8
strains used to raise the hyper-immune sera were cross-checked
against 2616 sera (since two animals were vaccinated against each
strain and each serum was checked in duplicate).
The data obtained from the HI assays demonstrated that on
occasions there existed large differences in the HI titres of sera
obtained from the two individual chickens vaccinated against the
same strain. In other words, animals in the same vaccination
group showed a considerable variation in the individual immune
response to the vaccine. In addition, because of the differences in
immune response observed occasionally between animals of the
same groups, the HI titres obtained from cross-checking the sera
from each group of two chickens against each one of the strains
show a different pattern of response in the two animals belonging
to the same vaccination group. However, the response pattern of
each serum is consistent across the strain spectrum. Furthermore,
in our analysis for the construction of the antigenic maps we have
averaged over these differences. Table 3 provides an overview of
the HI data.
The calculated distance matrices for viruses and sera are shown
in Tables S2 and S3 respectively in File S1. All distances are log2
values, therefore, a distance of 2 represents a difference value of 4
units in the HI test. Table S5 in File S1 shows the distance matrix
for all CVI isolates.
The antigenic maps showing the standardised real differences
(log2 titres) between different subsets of three strains or sera are
shown in Figures 2 and 3, respectively.
According to the antigenic map of the strains (Figure 2), the
antigenic distance between the CVI parent strain (H5N1 t/T) and
CVI P20 or CVI P42 isolates is 1.4 and 2.17 respectively.
Likewise, the distance between the FLI parent strain (H5N1 R65)
and the FLI P18esc or FLI P30esc is 2.64 and 3.3 respectively.
Both parent strains are antigenically similar, with a 0.84 distance
between them. As expected, the distance between H5N1 t/T and
the H5N2 or H5N3 viruses is very large (6.17 and 5.29
respectively). Similar results are obtained when comparing the
H5N1 R65 to the same two viruses (6.34 and 5.42 respectively).
From the antigenic map of the sera (Figure 3) a similar picture
to the map of the strains can be seen. Explanatory, the distance
between sera generated against H5N1 t/T and the CVI P20 or
CVI P42 isolates is 1.44 and 1.8 respectively and between H5N1
R65 and FLI P18esc or FLI P30esc is 2.95 and 3.16 respectively.
Distance of sera generated against H5N1 t/T and H5N1 R65 is
1.56. Finally, the antigenic distance between sera generated
against H5N1 t/T and the two reference strains (H5N2 and
H5N3) is 4.58 and 4.07 respectively. Similar results are obtained
when comparing the antigenic distance of the last two strains
against H5N1 R65 (3.71 and 4.14 respectively).
Comparison of Erythrocyte Binding Ability between
H5N1 t/T and CVI P42
Erythrocyte binding assays were performed in a timed manner
using the H5N1 t/T and CVI P42 strains. The results showed no
difference in the ability to bind to erythrocytes between the two
strains. In detail, the kinetics of virus binding were comparable for
both strains (from log104.383 to log103.199 for H5N1 t/T and
from log104.912 to log104.180 for CVI P42). Similar reductions in
virus quantity were observed during the intermediate time points
in the assay. An interesting observation that emerged from the
timed erythrocyte binding assays was that binding of virus to
erythrocytes appeared to be a rapid process in that most of the
binding appeared to take place very early in the incubation period
(i.e. within the first 10–15 minutes). After this time period, the
number of virus particles present in the supernatant appeared to
plateau. The results of the erythrocyte binding assays are shown in
Figure S2 in File S1.
Discussion
In this report we studied the effect of immune pressure (by
means of polyclonal sera directed against the HA protein) on the
evolution and mutant selection of HPAI H5N1 viruses, as well as
Table 2. Summary of amino acid mutations found in the HA protein of CVI P42, and their locations in respect to antigenically-
relevant regions.
Isolate
H5 A/turkey/Turkey/1/05
Numbering
H5 A/goose/Guangdong/
1/96 Numbering Location
CVI P42 R156M R140M AS (Epitope B), PS Site, AP
R205K R189K AS (RBS), PS Site, AP
P210S P194S AP
M242I M226I AS (Epitope D)
A254T A238T NA
Amino acid numbers are shown according to A/turkey/Turkey/1/05 (H5N1) and the reference strain A/goose/Guangdong/1/96 (H5N1) numbering (the latter numbering
is used throughout the report unless stated otherwise). Mutations found in common between CVI and FLI isolates are shown in bold. The locations of amino acid
substitutions in respect to antigenically relevant regions – according to Duvvuri, et al., (2009) – are shown in the last column (where available). AS: Antigenic Site; PS Site:
Positive Selection Site; AP: Antigenic Peptide; RBS: Receptor Binding Site; NA: Not Assigned a function.
doi:10.1371/journal.pone.0084628.t002
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examined the genetic and antigenic differences of the mutants
resulting from this pressure.
The results from the sequencing of the HA gene of our mutants
lead to some interesting observations.
Sequencing analysis of passage isolates showed that most of the
selection takes place early on, with the first amino acid mutation
identified as early as CVI P5. In addition, amino acid mutations
accumulate with increased passage number. In detail, CVI P5
demonstrated one amino acid mutation in the HA protein
(P194S), while in CVI P10 and P15 a second amino acid mutation
is present (M226I). CVI P20 has a third amino acid mutation
(A238T). Thus, by keeping the serum pressure constant (1:400
dilution) for the first 20 passages, three amino acid mutations were
identified in the HA protein. After passage 20, the serum pressure
was increased and this resulted in the selection of two more amino
acid mutations, namely R140M and R189K from CVI P35
onwards. These isolates were selected with a 1:5 dilution of
immune polyclonal sera. These results also show that amino acid
mutations found in early passages are carried over to later ones,
suggesting they are associated with an increased ability to
withstand immune serum pressure as a result of the selection
process and are not random mutations.
In addition, the fact that no amino acid substitutions were found
in the CVI control isolates indicates that the mutations found in
the isolates selected under immune pressure cannot be attributed
to events such as adaptation to the culture system or random drift
due to replication errors.
Table 3. HI data of strains and sera used for construction of antigenic maps.
Sera Strains
Vaccine Groups Animal Numbers CVI FLI Other
H5N1 t/T P20 P42 H5N1 R65 P18esc P30esc H5N2 H5N3
H5N1 t/T 376 256 128 256 256 128 64 32 64
128 128 512 128 128 64 32 64
377 1024 512 1024 1024 1024 128 64 64
1024 512 1024 1024 1024 128 64 128
CVI P20 378 2048 2048 1024 1024 2048 2048 256 256
1024 1024 1024 1024 2048 1024 256 256
379 512 256 512 256 512 128 64 64
256 256 512 512 256 128 64 64
CVI P42 742 512 256 1024 512 128 128 64 64
256 512 1024 256 128 256 64 64
743 512 512 1024 256 256 128 256 128
256 256 1024 256 256 128 256 128
H5N1 R65 380 512 256 256 512 256 32 32 128
512 128 256 1024 512 64 64 128
381 256 256 256 256 64 32 256 32
256 256 256 256 128 32 256 32
FLI P18esc 382 128 64 128 128 512 128 32 64
128 64 128 128 512 128 32 64
383 512 256 256 512 1024 256 64 128
256 256 256 512 1024 256 64 128
FLI P30esc 384 64 32 64 64 64 128 4 16
32 64 128 64 64 128 4 16
385 128 64 256 128 128 128 16 32
128 128 256 128 128 128 16 32
H5N2 386 64 16 32 64 32 8 1024 64
64 32 32 64 32 8 1024 64
387 64 64 64 64 128 64 1024 64
64 64 64 64 128 64 1024 64
H5N3 744 512 128 128 512 1024 128 256 2048
512 128 128 256 1024 128 256 2048
745 64 32 128 64 128 64 64 512
64 32 128 64 64 64 64 1024
In total, 16 sera were raised against 8 strains (2 sera/strain). Each serum (represented by animal number) was checked in duplicate against each one of the strains to
record antigenic differences between them.
doi:10.1371/journal.pone.0084628.t003
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Finally, due to the way our selection was carried out, we can
exclude the possibility that the CVI mutants were selected due to
their increased ability to bind to cells as suggested by Hensley et al.,
[55], since the CVI selection process was cell-free. Indeed,
erythrocyte binding assays showed that CVI P42 does not exhibit
an increased ability in binding to erythrocytes compared to H5N1
t/T (Figure S2 in File S1). This finding adds credibility to the
notion that the mutations found in the CVI isolates can indeed be
attributed to directional selection resulting from the polyclonal
sera used in this study. Furthermore, if the selection was driven by
differences in cell-receptor binding between our parent strain and
mutants and not by serum pressure, then some or all of the
mutations found in the CVI isolates selected under immune
pressure should have also been found in the CVI control isolates,
which was not the case, since no mutations were found in these
isolates. This is a further indication that we selected for viruses
with lower avidity for antibody binding but not necessarily with
lower avidity for cell-receptor binding. The results from the
extensive HI experiments confirm the difference in antibody
binding avidity between the parent strains and the mutants and
between the mutants themselves. Nevertheless, it should be
pointed out that despite the fact that our results show no
difference in binding to erythrocytes between the parent strain and
CVI P42, more sophisticated methods may be used to identify
subtle differences in receptor-binding avidity or receptor specific-
ity. Furthermore, whether any of the mutations found in our
isolates – singly or in combination – would have an effect on cell-
receptor binding avidity is a matter of future investigation.
A comparison between the amino acid mutations found in CVI
and FLI isolates is shown in Table 4. Intriguingly, two of the
amino acid mutations found in early CVI passage isolates (P194S
and M226I) were also found in early FLI passage isolates (starting
from FLI P18esc). These mutations are shown in bold in Table 4.
Considering that isolates between the two groups were selected
independently by different types of immune pressure (homologous
sera in the case of CVI as opposed to heterologous sera in FLI) and
in two different culture systems (ECEs in CVI as opposed to
MDCK cells in FLI) and adding the fact that these two mutations
were selected early in the procedure, it would appear that the
P194S and M226I mutations are particularly significant in H5N1
viruses stemming from the Guangdong lineage when adapting to
immune pressure. All other mutations reported in Table 4 are
unique to each group.
Phylogenetic analysis using the Maximum Likelihood method
based on the Tamura-Nei model [56] showed that both CVI P20
and CVI P42 branched out from their parent strain (data not
shown). A phylogenetic tree with the same strains constructed
Figure 2. Antigenic map of sets of strains used in this study. Antigenic map showing the standardized real distances between different sets of
three strains. Distances are in log2 values. Antigenic distance between H5N1 t/T and CVI P20 or CVI P42 is 1.4 and 2.17 respectively. Distance between
H5N1 R65 and FLI P18esc or FLI P30esc is 2.64 and 3.3 respectively. Both parent strains (H5N1 t/T and H5N1 R65) are antigenically similar (distance of
0.84). Both parent strains are very antigenically distant to the H5N2 and H5N3 strains used in the study. In detail, the distance between H5N1 t/T and
H5N2 or H5N3 is 6.17 and 5.29 respectively, while the distance between H5N1 R65 and H5N2 or H5N3 is 6.34 and 5.42 respectively (all distances can
be found in Table S2 in File S1).
doi:10.1371/journal.pone.0084628.g002
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using the Neighbour-Joining method [57] showed similar results
(data not shown).
These results confirm the genetic divergence of our mutants.
The same applies for the FLI P18esc and FLI P30esc isolates. As
expected, all isolates are genetically different from the H5N2 and
H5N3 strains, more so than from the ancestral A/goose/
Guangdong/1/96 strain.
In accordance with other reports [38,46,58–60], most of the
mutations found in the CVI P20 and P42 isolates are located
within known antigenic sites and sites known to be influenced by
selection pressure (Table 2). A notable exception is mutation
A238T, which is located in a position not yet assigned an antigenic
function.
Due to the positioning of our mutations it is not surprising that
the same amino acid mutations found in our isolates or different
amino acid mutations found in the same positions have been
associated with a wide variety of functions ranging from antigenic
drift, genetic diversity and even increased recognition of human
type Sialic Acid (SA) a2,6 receptors. An overview of the suggested
functions and implications of these mutations follows.
Two of the positions where mutations were found in the CVI
mutants (namely 140 and 226) have been identified in viruses
isolated from vaccinated chickens in Egypt, with position 140
possibly being implicated in immune escape. In detail, research on
Figure 3. Antigenic map of sets of sera raised against the strains used in this study. Antigenic map showing the standardized real
distances between different sets of three sera. Distances are in log2 values. Antigenic distance between sera from H5N1 t/T and CVI P20 or CVI P42 is
1.44 and 1.8 respectively. Distance between sera from H5N1 R65 and FLI P18esc or FLI P30esc is 2.95 and 3.16 respectively. Sera raised against the
parent strains (H5N1 t/T and H5N1 R65) have a distance of 1.56. Sera raised against H5N1 t/T and H5N1 R65 are very antigenically distant to sera
raised against the H5N2 and H5N3 strains used in the study. In detail, the distance between sera raised against H5N1 t/T and H5N2 or H5N3 is 4.58
and 4.07 respectively, while the distance between sera raised against H5N1 R65 and H5N2 or H5N3 is 3.71 and 4.14 respectively (all distances can be
found in Table S3 in File S1).
doi:10.1371/journal.pone.0084628.g003
Table 4. Summary and Comparison of Amino Acid Mutations
found in the HA protein of CVI and FLI Isolates.
CVI P5 CVI P10 CVI P15 CVI 20 CVI P42 FLI P18esc FLI P30esc
N72D
K119N
R140M
S141P
K152E K152E
R189K
P194S P194S P194S P194S P194S P194S P194S
T195A
M226I M226I M226I M226I M226I M226I
A238T A238T
Y271H
Mutations in bold indicate mutations found by both groups. Numbers refer to
the A/goose/Guangdong/1/1996 (Influenza Research Database accession
number AF144305) HA amino acid sequence.
doi:10.1371/journal.pone.0084628.t004
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avian isolates circulating in Egypt (where vaccination is applied
both to commercial and backyard poultry, albeit with variable
degrees of coverage ranging from around 50% in commercial
poultry to 1–25% in household flocks), has shown that a particular
2008 H5N1 isolate is genetically and antigenically different from
2006–2007 isolates [46]. In total, 12 amino acid substitutions were
found in the 2008 isolate, 11 of which occurred in the RBS, in
locations that are proximal to the functional regions, represented
by the 190 a-helix, the 130-loop and the 220-loop. The authors
found that mutations in 5 key amino acid positions (including
position 140) resulted in reduced HI titres (when compared to the
2007 H5N1 strain not carrying these mutations) and that this
effect was produced by substitutions in position 140, either singly
or in combination with other substitutions. As a consequence,
mutations in these positions appear to be primarily involved in
antigenic drift and progressive accumulation of mutations at
multiple antigenic sites of the HA1 molecule can enhance
antigenic drift, leading to an increased chance of escaping immune
responses [46,59]. In agreement with previous reports
[38,58,60,61], an amino acid mutation in position 226 does not
appear to contribute to antigenic drift, since this area of the
protein is not exposed to the surface of the HA antigen [46].
Nevertheless, the fact that a mutation in this position (M226I) was
identified in both the CVI and FLI isolates could allow us to
speculate that it has an effect in virus survival and adaptation to
immune pressure.
Additional research on Egyptian isolates reported a number of
mutations – some of which in the same positions identified in the
CVI isolates and some (P194S, M226I and A238T) being identical
to the ones found in CVI P10 throughout CVI P42 – resulting in
two different sub-lineages of viruses, one falling in the 2.2.1 clade
and the other one being a variant group comprising a new 2.2.1.1
sub-clade. The viruses belonging to these groups were reported to
have undergone significant antigenic drift and their HAs not to be
cross-immunogenic with the HAs of other sub-lineages. The fact
that these mutations were found in isolates that were circulating in
vaccinated birds, coupled with the position of these mutations, is a
strong suggestion that suboptimal vaccination may have been the
driving force in the selection of these mutants [46,62–64].
In addition, two of the selected mutations found in the CVI
isolates (R189K and M226I) were also found in HPAI H5N1
isolates circulating in Pakistan during the 2006–2008 outbreak,
indicating increased genetic diversity of Pakistani isolates during
that period [65].
Finally, the same A238T mutation we found in the CVI isolates
(as well as mutations at positions 140, 189 and 194) have been
identified in virus isolates circulating in poultry in China from
2007–2009 [66].
Figure 4. Comparison of positions of HA amino acid mutations found in CVI P42 and FLI P30esc. Positions of mutations in the HA
protein found in CVI P42 (yellow bars) and FLI P30esc isolates (green bars) relative to the HA protein sequences of A/turkey/Turkey/1/2005 and
A/Cygnus cygnus/Germany/R65/2006. Red bars indicate the two amino acid mutations (P210S, M242I) found in common between CVI P42and FLI
P30esc isolates. The positions of the 130- and 220-loop and 190 helix are shown in orange boxes. The blue arrow indicates the proteolytic cleavage
site between HA1 and HA2. Numbering according to the A/turkey/Turkey/1/05.
doi:10.1371/journal.pone.0084628.g004
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Literature suggests that mutations in or around the 130, 220
loops and the 190 a-helix play a significant role in receptor-type
switching [38,46]. As such, it is not surprising that one of the
mutations reported here (M226I) as well as a second mutation not
similar to our isolate’s but at the same position (R140K), were
found in other studies to be associated with an increased affinity
for human SA a2,6Gal receptors, thus possibly making these
amino acid positions a key to potential avian-to-human transmis-
sion [8,67]. Figure 4 shows the positions of our mutations relevant
to these loops. Although substitutions in proteins other than the
HA may be necessary before an avian strain gains full pandemic
status, the HA amino acid substitutions that result in a change in
the affinity from avian to human receptors may be used as markers
for vigilance against H5N1 strains that are capable of replicating
in humans [67]. Therefore, it is worth studying if any of the
mutants reported here show any increased binding affinity to
human SA a2,6Gal receptors, as well as whether there is a change
in the avian SA a2,3Gal receptors binding affinity of the mutants
compared to the parent strains.
Mutation R189K in the HA of an Oseltamivir-resistant human
H1N1 virus (A/Tottori/52/08) was found to be critical to viruses
with an Oseltamivir-resistant NA 274Y for achieving viral titres
similar to that of viruses carrying an Oseltamivir-sensitive NA
274H. This increases the implications of mutations in this
particular region of the HA [68]. The same mutation has also
been found in isolates from patients affected by the human H1N1
2009 pandemic virus in Portugal, Italy, Japan, Canada and
Taiwan among other places [69–74]. Mutation R189K has also
been found in the consensus HA1 sequences of avian and human
H5N1 viruses (Hu, 2010). Literature suggests that another one of
the mutations found in both the CVI and FLI isolates (P194S) may
also be associated with selection due to Oseltamivir pressure and
decreased binding to SA a2,6 receptors probably due to the
acquisition of a potential glycosylation site [75]. Indeed, our results
demonstrate that this mutation did result in an additional potential
glycosylation site as shown in Figure 4. An increase in the number
of glycosylation sites has been known to occur at high frequency in
the early stages of evolution and may play a role in host adaptation
[76]. Additionally, a study by Igarashi [77] suggests that H5 avian
influenza viruses are able to acquire N-glycosylation sequons more
rapidly than other HA subtypes and other past pandemic viruses.
Antigenic characterisation of the CVI mutants by means of
antigenic cartography showed that the antigenic distance between
them and the parent strain H5N1 t/T increases with passage
number. However, our maps also seem to indicate a diminishing
rate of return with increasing passage number. Taken together
these results seem to support our previous notion that most of the
selection takes place early in the rounds of selection. The same
holds true for the distances observed between the FLI isolates and
their parent strain H5N1 R65. Our antigenic maps further
demonstrate the very large distance between H5N1 t/T or H5N1
R65 and the two reference strains (H5N2 and H5N3). As
expected, these distances are much larger than the distance
between the parent strains and their mutants. Comparable results
were found when comparing the antigenic distances of sera
originating from each of the parent strains and mutants mentioned
above. It is worth mentioning that the main advantages in the
construction of our maps are that they maintain true antigenic
distances and avoid the distortion that would result when mapping
a 16-dimensional space unto a 2-dimensional one.
The fact that most of the mutations found in the CVI isolates
have also been found in chicken in nature is encouraging since it
gives credence to our selection procedure as being a valid
approach to studying selection of avian influenza mutants. This
suggests that our selection method may have relevance to field
situations.
It remains to be investigated whether the antigenic distance
between our isolates and parent strain is sufficient to allow
transmission of the isolates in animals vaccinated against the
parent strain or vice versa, thus allowing us to really name these
isolates escape mutants. Depending on the outcome of such
studies, appropriate recommendations regarding vaccine updates
can be made.
Supporting Information
File S1 Supplemental Tables S1–S5 and Supplemental
Figures S1–S2.
(PDF)
Acknowledgments
The authors would like to acknowledge Dr. Alan Rigter for his help in the
initial experiments, Dr. Guus Koch for his insight and help in the
phylogenetic analysis and Mrs. Linda McPhee for her help in proofreading
the manuscript.
Author Contributions
Conceived and designed the experiments: IS BP MCMDJ. Performed the
experiments: IS. Analyzed the data: IS BP MCMDJ. Contributed
reagents/materials/analysis tools: BP DK MB. Wrote the paper: IS BP
MCMDJ. Read and corrected manuscript: DK MB.
References
1. Alexander DJ (2000) A review of avian influenza in different bird species. Vet
Microbiol 74: 3–13.
2. Fouchier RA, Munster V, Wallensten A, Bestebroer TM, Herfst S, et al. (2005)
Characterization of a novel influenza A virus hemagglutinin subtype (H16)
obtained from black-headed gulls. J Virol 79: 2814–2822.
3. Webster RG, Bean WJ, Gorman OT, Chambers TM, Kawaoka Y (1992)
Evolution and ecology of influenza A viruses. Microbiol Rev 56: 152–179.
4. Wan H, Sorrell EM, Song H, Hossain MJ, Ramirez-Nieto G, et al. (2008)
Replication and transmission of H9N2 influenza viruses in ferrets: evaluation of
pandemic potential. PLoS One 3: e2923.
5. Gerhard W, Webster RG (1978) Antigenic drift in influenza A viruses. I.
Selection and characterization of antigenic variants of A/PR/8/34 (HON1)
influenza virus with monoclonal antibodies. J Exp Med 148: 383–392.
6. Chakrabarti AK, Pawar SD, Cherian SS, Koratkar SS, Jadhav SM, et al. (2009)
Characterization of the influenza A H5N1 viruses of the 2008-09 outbreaks in
India reveals a third introduction and possible endemicity. PLoS One 4: e7846.
7. Matrosovich M, Zhou N, Kawaoka Y, Webster R (1999) The surface
glycoproteins of H5 influenza viruses isolated from humans, chickens, and wild
aquatic birds have distinguishable properties. J Virol 73: 1146–1155.
8. Ubol S, Suksatu A, Modhiran N, Sangma C, Thitithanyanont A, et al. (2011)
Intra-host diversities of the receptor-binding domain of stork faeces-derived
avian H5N1 viruses and its significance as predicted by molecular dynamic
simulation. J Gen Virol 92: 307–314.
9. Webster RG, Laver WG, Air GM, Schild GC (1982) Molecular mechanisms of
variation in influenza viruses. Nature 296: 115–121.
10. Wilson IA, Cox NJ (1990) Structural basis of immune recognition of influenza
virus hemagglutinin. Annu Rev Immunol 8: 737–771.
11. Stevens J, Blixt O, Tumpey TM, Taubenberger JK, Paulson JC, et al. (2006)
Structure and receptor specificity of the hemagglutinin from an H5N1 influenza
virus. Science 312: 404–410.
12. Nelson MI, Holmes EC (2007) The evolution of epidemic influenza. Nat Rev
Genet 8: 196–205.
13. Hafez MH, Arafa A, Abdelwhab EM, Selim A, Khoulosy SG, et al. (2010) Avian
influenza H5N1 virus infections in vaccinated commercial and backyard poultry
in Egypt. Poult Sci 89: 1609–1613.
14. Bouvier NM, Palese P (2008) The biology of influenza viruses. Vaccine 26 Suppl
4: D49–53.
Influenza Mutant Selection with Polyclonal Sera
PLOS ONE | www.plosone.org 11 February 2014 | Volume 9 | Issue 2 | e84628
15. Van Borm S, Ferreira HL, van den Berg T (2010) Fine quantification of avian
influenza H5N1 escape mutant quasispecies populations using mutation-specific
real-time PCR. Avian Dis 54: 558–564.
16. Domingo E (1997) RNA virus evolution, population dynamics, and nutritional
status. Biol Trace Elem Res 56: 23–30.
17. Duarte EA, Novella IS, Weaver SC, Domingo E, Wain-Hobson S, et al. (1994)
RNA virus quasispecies: significance for viral disease and epidemiology. Infect
Agents Dis 3: 201–214.
18. Drake JW (1999) The distribution of rates of spontaneous mutation over viruses,
prokaryotes, and eukaryotes. Ann N Y Acad Sci 870: 100–107.
19. Eigen M (1993) Viral quasispecies. Sci Am 269: 42–49.
20. UN FAO (2012) H5N1 HPAI Global Overview January-March 2012.
21. WHO (2011) Avian Influenza Fact Sheet.
22. Beigel JH, Farrar J, Han AM, Hayden FG, Hyer R, et al. (2005) Avian influenza
A (H5N1) infection in humans. N Engl J Med 353: 1374–1385.
23. Cinatl J Jr., Michaelis M, Doerr HW (2007) The threat of avian influenza A
(H5N1). Part I: Epidemiologic concerns and virulence determinants. Med
Microbiol Immunol 196: 181–190.
24. Li KS, Guan Y, Wang J, Smith GJ, Xu KM, et al. (2004) Genesis of a highly
pathogenic and potentially pandemic H5N1 influenza virus in eastern Asia.
Nature 430: 209–213.
25. Medina RA, Garcia-Sastre A (2011) Influenza A viruses: new research
developments. Nat Rev Microbiol 9: 590–603.
26. Webster RG, Peiris M, Chen H, Guan Y (2006) H5N1 outbreaks and enzootic
influenza. Emerg Infect Dis 12: 3–8.
27. Herfst S, Schrauwen EJ, Linster M, Chutinimitkul S, de Wit E, et al. (2012)
Airborne transmission of influenza A/H5N1 virus between ferrets. Science 336:
1534–1541.
28. Imai M, Watanabe T, Hatta M, Das SC, Ozawa M, et al. (2012) Experimental
adaptation of an influenza H5 HA confers respiratory droplet transmission to a
reassortant H5 HA/H1N1 virus in ferrets. Nature 486: 420–428.
29. Russell CA, Fonville JM, Brown AE, Burke DF, Smith DL, et al. (2012) The
potential for respiratory droplet-transmissible A/H5N1 influenza virus to evolve
in a mammalian host. Science 336: 1541–1547.
30. Nishiura H, Yen HL, Cowling BJ (2013) Sample size considerations for one-to-
one animal transmission studies of the influenza A viruses. PLoS One 8: e55358.
31. Swayne DE (2012) Impact of vaccines and vaccination on global control of avian
influenza. Avian Dis 56: 818–828.
32. Swayne DE (2012) The role of vaccines and vaccination in high pathogenicity
avian influenza control and eradication. Expert Rev Vaccines 11: 877–880.
33. Pavade G, Awada L, Hamilton K, Swayne DE (2011) The influence of economic
indicators, poultry density and the performance of veterinary services on the
control of high-pathogenicity avian influenza in poultry. Rev Sci Tech 30: 661–
671.
34. Swayne DE, Pavade G, Hamilton K, Vallat B, Miyagishima K (2011)
Assessment of national strategies for control of high-pathogenicity avian
influenza and low-pathogenicity notifiable avian influenza in poultry, with
emphasis on vaccines and vaccination. Rev Sci Tech 30: 839–870.
35. Grund C, Abdelwhab el SM, Arafa AS, Ziller M, Hassan MK, et al. (2011)
Highly pathogenic avian influenza virus H5N1 from Egypt escapes vaccine-
induced immunity but confers clinical protection against a heterologous clade
2.2.1 Egyptian isolate. Vaccine 29: 5567–5573.
36. Kaverin NV, Rudneva IA, Ilyushina NA, Varich NL, Lipatov AS, et al. (2002)
Structure of antigenic sites on the haemagglutinin molecule of H5 avian
influenza virus and phenotypic variation of escape mutants. J Gen Virol 83:
2497–2505.
37. Kaverin NV, Rudneva IA, Ilyushina NA, Lipatov AS, Krauss S, et al. (2004)
Structural differences among hemagglutinins of influenza A virus subtypes are
reflected in their antigenic architecture: analysis of H9 escape mutants. J Virol
78: 240–249.
38. Kaverin NV, Rudneva IA, Govorkova EA, Timofeeva TA, Shilov AA, et al.
(2007) Epitope mapping of the hemagglutinin molecule of a highly pathogenic
H5N1 influenza virus by using monoclonal antibodies. J Virol 81: 12911–12917.
39. Gitelman AK, Kaverin NV, Kharitonenkov IG, Rudneva IA, Sklyanskaya EL,
et al. (1986) Dissociation of the haemagglutination inhibition and the infectivity
neutralization in the reactions of influenza A/USSR/90/77 (H1N1) virus
variants with monoclonal antibodies. J Gen Virol 67 (Pt 10): 2247–2251.
40. Philpott M, Easterday BC, Hinshaw VS (1989) Neutralizing epitopes of the H5
hemagglutinin from a virulent avian influenza virus and their relationship to
pathogenicity. J Virol 63: 3453–3458.
41. Tsuchiya E, Sugawara K, Hongo S, Matsuzaki Y, Muraki Y, et al. (2002) Effect
of addition of new oligosaccharide chains to the globular head of influenza A/
H2N2 virus haemagglutinin on the intracellular transport and biological
activities of the molecule. J Gen Virol 83: 1137–1146.
42. Yewdell JW, Caton AJ, Gerhard W (1986) Selection of influenza A virus
adsorptive mutants by growth in the presence of a mixture of monoclonal
antihemagglutinin antibodies. J Virol 57: 623–628.
43. Lambkin R, McLain L, Jones SE, Aldridge SL, Dimmock NJ (1994)
Neutralization escape mutants of type A influenza virus are readily selected by
antisera from mice immunized with whole virus: a possible mechanism for
antigenic drift. J Gen Virol 75 (Pt 12): 3493–3502.
44. Archetti I, Horsfall FL Jr. (1950) Persistent antigenic variation of influenza A
viruses after incomplete neutralization in ovo with heterologous immune serum.
J Exp Med 92: 441–462.
45. Lee CW, Senne DA, Suarez DL (2004) Effect of vaccine use in the evolution of
Mexican lineage H5N2 avian influenza virus. J Virol 78: 8372–8381.
46. Cattoli G, Milani A, Temperton N, Zecchin B, Buratin A, et al. (2011) Antigenic
drift in H5N1 avian influenza virus in poultry is driven by mutations in major
antigenic sites of the hemagglutinin molecule analogous to those for human
influenza virus. J Virol 85: 8718–8724.
47. Park KJ, Kwon HI, Song MS, Pascua PN, Baek YH, et al. (2011) Rapid
evolution of low-pathogenic H9N2 avian influenza viruses following poultry
vaccination programmes. J Gen Virol 92: 36–50.
48. Donald HB, Isaacs A (1954) Counts of influenza virus particles. J Gen Microbiol
10: 457–464.
49. UN OIE (2012) Manual of Diagnostic Tests and Vaccines For Terrestrial
Animals (Mammals, Birds and Bees). 7th Edition ed.
50. Smith DJ, Lapedes AS, de Jong JC, Bestebroer TM, Rimmelzwaan GF, et al.
(2004) Mapping the antigenic and genetic evolution of influenza virus. Science
305: 371–376.
51. Smith DJ, Lapedes AS, de Jong JC, Bestebroer TM, Jones TC, et al. (2004)
Mutations, drift, and the influenza archipelago. Discov Med 4: 371–377.
52. Fouchier RA, Smith DJ (2010) Use of antigenic cartography in vaccine seed
strain selection. Avian Dis 54: 220–223.
53. Cai Z, Zhang T, Wan XF (2010) A computational framework for influenza
antigenic cartography. PLoS Comput Biol 6: e1000949.
54. Hoper D, Kalthoff D, Hoffmann B, Beer M (2012) Highly pathogenic avian
influenza virus subtype H5N1 escaping neutralization: more than HA variation.
J Virol 86: 1394–1404.
55. Hensley SE, Das SR, Bailey AL, Schmidt LM, Hickman HD, et al. (2009)
Hemagglutinin receptor binding avidity drives influenza A virus antigenic drift.
Science 326: 734–736.
56. Tamura K, Nei M (1993) Estimation of the number of nucleotide substitutions in
the control region of mitochondrial DNA in humans and chimpanzees. Mol Biol
Evol 10: 512–526.
57. Saitou N, Nei M (1987) The neighbor-joining method: a new method for
reconstructing phylogenetic trees. Mol Biol Evol 4: 406–425.
58. Duvvuri VR, Duvvuri B, Cuff WR, Wu GE, Wu J (2009) Role of positive
selection pressure on the evolution of H5N1 hemagglutinin. Genomics
Proteomics Bioinformatics 7: 47–56.
59. Shih AC, Hsiao TC, Ho MS, Li WH (2007) Simultaneous amino acid
substitutions at antigenic sites drive influenza A hemagglutinin evolution. Proc
Natl Acad Sci U S A 104: 6283–6288.
60. Wu WL, Chen Y, Wang P, Song W, Lau SY, et al. (2008) Antigenic profile of
avian H5N1 viruses in Asia from 2002 to 2007. J Virol 82: 1798–1807.
61. Kolaskar AS, Tongaonkar PC (1990) A semi-empirical method for prediction of
antigenic determinants on protein antigens. FEBS Lett 276: 172–174.
62. Watanabe Y, Ibrahim MS, Ellakany HF, Kawashita N, Daidoji T, et al. (2012)
Antigenic analysis of highly pathogenic avian influenza virus H5N1 sublineages
co-circulating in Egypt. J Gen Virol 93: 2215–2226.
63. Arafa A, Suarez D, Kholosy SG, Hassan MK, Nasef S, et al. (2012) Evolution of
highly pathogenic avian influenza H5N1 viruses in Egypt indicating progressive
adaptation. Arch Virol 157: 1931–1947.
64. Abdelwhab EM, Arafa AS, Stech J, Grund C, Stech O, et al. (2012) Diversifying
evolution of highly pathogenic H5N1 avian influenza virus in Egypt from 2006
to 2011. Virus Genes 45: 14–23.
65. Siddique N, Naeem K, Abbas MA, Ahmed Z, Malik SA (2012) Sequence and
phylogenetic analysis of highly pathogenic avian influenza H5N1 viruses isolated
during 2006–2008 outbreaks in Pakistan reveals genetic diversity. Virol J 9: 300.
66. Jiang WM, Liu S, Chen J, Hou GY, Li JP, et al. (2010) Molecular
epidemiological surveys of H5 subtype highly pathogenic avian influenza viruses
in poultry in China during 2007–2009. J Gen Virol 91: 2491–2496.
67. Yamada S, Suzuki Y, Suzuki T, Le MQ, Nidom CA, et al. (2006)
Haemagglutinin mutations responsible for the binding of H5N1 influenza A
viruses to human-type receptors. Nature 444: 378–382.
68. Ginting TE, Shinya K, Kyan Y, Makino A, Matsumoto N, et al. (2012) Amino
acid changes in hemagglutinin contribute to the replication of oseltamivir-
resistant H1N1 influenza viruses. J Virol 86: 121–127.
69. Piralla A, Pariani E, Rovida F, Campanini G, Muzzi A, et al. (2011) Segregation
of virulent influenza A(H1N1) variants in the lower respiratory tract of critically
ill patients during the 2010–2011 seasonal epidemic. PLoS One 6: e28332.
70. Dapat IC, Dapat C, Baranovich T, Suzuki Y, Kondo H, et al. (2012) Genetic
characterization of human influenza viruses in the pandemic (2009–2010) and
post-pandemic (2010–2011) periods in Japan. PLoS One 7: e36455.
71. Graham M, Liang B, Van Domselaar G, Bastien N, Beaudoin C, et al. (2011)
Nationwide molecular surveillance of pandemic H1N1 influenza A virus
genomes: Canada, 2009. PLoS One 6: e16087.
72. Kao CL, Chan TC, Tsai CH, Chu KY, Chuang SF, et al. (2012) Emerged HA
and NA mutants of the pandemic influenza H1N1 viruses with increasing
epidemiological significance in Taipei and Kaohsiung, Taiwan, 2009-10. PLoS
One 7: e31162.
73. ECDC (2011) Surveillance Report: Influenza Virus Characterisation. Summary
Europe, February 2011.
74. Portuguese Laboratory Network for the Diagnosis of Influenza I (2012)
Contribution of the Portuguese Laboratory Network for the Diagnosis of
Influenza A(H1N1)pdm09 infection during the 2009/10 and 2010/11 influenza
seasons. Euro Surveill 17.
Influenza Mutant Selection with Polyclonal Sera
PLOS ONE | www.plosone.org 12 February 2014 | Volume 9 | Issue 2 | e84628
75. Ilyushina NA, Bovin NV, Webster RG (2012) Decreased neuraminidase activity
is important for the adaptation of H5N1 influenza virus to human airway
epithelium. J Virol 86: 4724–4733.
76. Sun S, Wang Q, Zhao F, Chen W, Li Z (2011) Glycosylation site alteration in
the evolution of influenza A (H1N1) viruses. PLoS One 6: e22844.
77. Igarashi M, Ito K, Kida H, Takada A (2008) Genetically destined potentials for
N-linked glycosylation of influenza virus hemagglutinin. Virology 376: 323–329.
Influenza Mutant Selection with Polyclonal Sera
PLOS ONE | www.plosone.org 13 February 2014 | Volume 9 | Issue 2 | e84628
